| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 |
| filingDate |
2017-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d357256e3ef41c306f58096afb7c82e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9653fd4ff3944c382816bb7eed551f21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_407d24eff7fdbb2fc7f6c83a5f9cebc3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3daaf39489bbaf521e26242fc73c0db7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0be7db66285be1c7c9361de62d1ba4d6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a103922842410944098f9ccdb222ac23 |
| publicationDate |
2018-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2018069893-A1 |
| titleOfInvention |
Methods for treating ocular disease using inhibitors of csf-1r |
| abstract |
The present invention provides in one aspect methods for treating ocular diseases by administering pharmaceutical compositions comprising an inhibitor of colony stimulating factor-1 (CSF-1) receptors. In another aspect, the present invention provides pharmaceutical compositions for treating ocular diseases, the compositions comprising at least one inhibitor of CSF-1R. The inhibitor can also be a selective inhibitor of CSF-1R in certain embodiments. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019173211-A1 |
| priorityDate |
2016-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |